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HIV/AIDS-related mortality accounts for almost one-third of 
deaths in South Africa (SA), and globally ~15% of AIDS-related 
mortality is associated with cryptococcal disease.[1,2] The burden of 
cryptococcal meningitis has remained high in SA among severely 
immunosuppressed HIV-positive patients, despite substantial 
improvements in antiretroviral treatment (ART) coverage over the 
past decade.[3] Approximately one-third of patients entering HIV care 
in the SA public sector in 2016 had advanced HIV disease (defined 
as a CD4+ T-lymphocyte count <200 cells/µL), and 17% had a CD4+ 
count <100 cells/µL.[4] In 2011, the World Health Organization 
(WHO) recommended that countries consider integrating crypto-
coccal antigen (CrAg) screening into HIV programmes to detect 
cryptococcal disease at an earlier point in its trajectory, followed 
by pre-emptive antifungal treatment to reduce AIDS deaths. [5] The 
CrAg screen-and-treat intervention therefore aligns with the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) over-arching 
goal to reduce global AIDS deaths to >500  000 by 2020, and has 
been included in a new WHO-recommended package of care for 
managing advanced HIV disease.[6] Since it was first included in 
SA’s national strategic plan for HIV/AIDS, tuberculosis and STIs 
in 2012, evidence has mounted in favour of the CrAg screen-and-
treat intervention. A randomised controlled trial from Zambia and 
Tanzania revealed that pre-ART CrAg screening with pre-emptive 
antifungal treatment for patients with a CD4+ count <200 cells/µL, 
coupled with 4 weeks of community-based ART adherence support, 
resulted in a 28% reduction in all-cause mortality at 12 months.[7]
In the light of these data, on 1 October 2016 the National Health 
Laboratory Service (NHLS) implemented a ground-breaking service 
to provide the world’s first and largest national laboratory-based 
CrAg screening programme aimed at detecting early cryptococcal 
disease before progression to meningitis in all HIV-seropositive 
patients with a CD4+ count <100 cells/µL across SA. The launch of 
the programme was the culmination of a long, successful, nationally 
co-ordinated effort by the National Institute for Communicable 
Diseases (NICD), the National Department of Health (NDoH), the 
NHLS and other local and international partners.
Several activities preceded this important milestone. Following a 
circular (circular no. H116/2012) from the Western Cape provincial 
government to screen all patients whose CD4+ count was <100 cells/
µL, a provider-initiated CrAg screening initiative was implemented in 
the Western Cape in mid-2012. No clinical training was offered, and 
no feedback was provided to clinicians in terms of the proportion of 
eligible patients screened at their clinics. A retrospective evaluation 
showed that just over a quarter of eligible patients were screened under 
this initiative; compared with those who were screened, those who 
were not screened were almost twice as likely to develop disseminated 
cryptococcal disease.[8] In contrast, a simpler laboratory-based 
approach using remnant CD4+ samples reflexively tested for CrAg 
if the CD4+ count was <100 cells/µL was simultaneously piloted in 
four districts in Gauteng and Free State provinces from 2012 through 
to 2015.[9,10] This initiative was paired with intensive clinician training 
on how to appropriately manage CrAg-positive patients identified 
through reflexed testing. In this scenario, almost 100% of eligible 
patients were screened for cryptococcal antigenaemia.
Implementation of these two contrasting approaches offered 
a valuable opportunity for parallel evaluation. A detailed cost-
effectiveness model demonstrated that laboratory-based reflex CrAg 
screening was simpler and more cost-effective than a clinician-
initiated approach, allowed for almost universal screening coverage, 
and potentially saved more lives.[11] In 2014, the NDoH adopted a 
detailed screen-and-treat clinical algorithm for seamless integration 
into the HIV care cascade. This algorithm has subsequently been 
included in the Standard Treatment Guidelines/Essential Medicines 
List at all healthcare levels.[12,13] Several skills-based training work-
shops for management of cryptococcal disease were developed and 
cascaded downwards to healthcare workers at facility level. On 
the NHLS side, the initiative facilitated the evaluation of several 
CrAg assays and workflow analyses for scaling up state laboratory 
services. [14-17] The NHLS also undertook intensive training of 
laboratory personnel based on standard operating procedures and 
on-site assessment of laboratory work flow, enabling integration into 
existing CD4+ services. The development of a national laboratory 
proficiency testing scheme (PTS) by the NICD/NHLS completed 
the final phase of service delivery implementation; the first batch 
of PTS samples was distributed to NHLS CD4+ laboratories in 
November 2016. On the NDoH side, a public health planning and 
resource allocation exercise was conducted, specifically to ensure that 
fluconazole was procured and made available at all healthcare levels.
A laboratory dashboard for CrAg has been integrated into a broader 
SA HIV programme dashboard, with two key indicators: CrAg 
screening coverage and prevalence of cryptococcal antigenaemia. 
Good linkage to laboratory CrAg results is the cornerstone of this 
programme. Several methods are being implemented to ensure 
that CrAg-positive patients return for clinical evaluation and 
begin appropriate antifungal treatment. Weekly CrAg results for 
action (RFA) reports are emailed to registered end-users (currently 
including district/facility managers or registered healthcare workers 
at 220 facilities in 32 districts). RFA reports are formatted as line-lists 
of patients with a positive CrAg result who need urgent follow-up.
Looking ahead, the impact of the CrAg screen-and-treat pro-
gramme on patient outcomes will be evaluated by clinic-based field 
surveys over the next 5 years through the NICD’s CAST-NET project. 
Several interventions will also be explored to optimise implementation 
of CrAg screen-and-treat, including intensive refresher healthcare 
worker training with novel methods of delivery, patient education, 
enhanced delivery of laboratory results to clinicians, and risk 
stratification of patients by piloting semi-quantitative CrAg testing 
on reflexively tested blood specimens.[18]
Through this national CrAg screening initiative, 276 125 patients 
were screened during the first year (October 2016 through to 
September 2017) with 95% coverage, and 15 757 (5.7%) were 
identified with cryptococcal antigenaemia,[19-21] highlighting both the 
large burden of advanced HIV disease and opportunistic infections 
in SA and the urgent need to recruit these very ill patients into care.
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